I. Medizinische Klinik und Poliklinik

Visual Universitätsmedizin Mainz
Zurück zur vorherigen Seite

Publikationen

Orginalarbeiten

  1. Schattenberg JM, Wang Y, Rigoli RM, Koop DR, Czaja MJ. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology. 2004; 39:444-455. IF: 10.885
  2. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J. Biol. Chem. 2005; 280:9887-9894. IF: 5.328
  3. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology; 2006; 43:163-172. IF: 10.885
  4. Schattenberg JM, Zimmermann T, Worns M, Sprinzl MF, Kreft A, Kohl T, Nagel M, Siebler J, Bergkamen HS, He YW, Galle PR, Schuchmann M. Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. 2011; J. Hepatol. 55:1272-1280. IF: 9.334
  5. Schattenberg JM, Worns MA, Zimmermann T, He YW, Galle PR, Schuchmann M. The role of death effector domain (DED)-containing proteins in acute oxidative cell injury in hepatocytes. Free Radic.Biol.Med. 2012; 52:1911-7. IF: 5.773
  6. Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am. J. Physiol Gastrointest. Liver Physiol. 2012; 303: G498-506. IF: 3.522
  7. Wang Y, Schattenberg JM, Rigoli RM, Storz P, Czaja MJ. Hepatocyte resistance to oxidative stress is dependent on protein kinase C-mediated down-regulation of c-Jun/AP-1. J. Biol. Chem. 2004; 279:31089-31097. IF: 5.328
  8. Benten D, Kumaran V, Joseph B, Schattenberg J, Popov Y, Schuppan D, Gupta S. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. 2005; Hepatology 42:1072-1081. IF: 10.885
  9. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Worns M, Fischer T, Strand S, Lohse AW, Galle PR. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards. Oncol. Rep. 2006; 15:227-230. IF: 1.686
  10. Singh R, Wang Y, Schattenberg JM, Xiang Y, Czaja MJ. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am. J. Physiol Gastrointest. Liver Physiol. 2009; 297:G907-17. IF: 3.522
  11. Zimmermann T, Otto C, Hoppe-Lotichius M, Biesterfeld S, Lautem A, Knaak M, Zimmermann A, Barreiros AP, Heise M, Schattenberg JM, Sprinzl MF, Galle PR, Otto G, Schuchmann M. Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation. Transplant. Proc. 2009; 41:2549-2556. IF: 0.993
  12. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, Schattenberg JM, Heise M, Biesterfeld S, Galle PR, Otto G, Schuchmann M. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). Eur. J. Intern. Med. 2010; 21:208-215. IF: 1.657
  13. Zimmermann, A, Zimmermann, T, Schattenberg, JM, Pottgen, S, Lotz, J, Rossmann, H, Roeddiger, R, Biesterfeld, S, Geiss, HC, Schuchmann, M, Galle, PR, Weber, MM. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome  Eur. J. Intern. Med. 2011; 22:305-310. IF: 1.657
  14. Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. 2012; J Clin Virol. 2012; 54:93-5. IF: 4.023
  15. Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer. 2012; 12:109. IF: 3.15
  16. Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M: Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012, 54:93-5. IF: 3.969
  17. Schattenberg JM, Nagel M, Kim YO, Kohl T, Worns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M: Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 2012, 303:G498-506. IF: 3.431
  18. Schattenberg JM, Worns MA, Zimmermann T, He YW, Galle PR, Schuchmann M: The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radic Biol Med 2012, 52:1911-7. IF: 5.432
  19. Kittner JM, Brokamp F, Jager B, Wulff W, Schwandt B, Jasinski J, Wedemeyer H, Schmidt RE, Schattenberg JM, Galle PR, Schuchmann M: Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. AIDS Care 2013. IF: 1.603
  20. Lautem A, Heise M, Grasel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, Zimmermann A, Otto G, Lang H, Galle PR, Schuchmann M, Zimmermann T: Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol 2013, 42:1297-304. IF: 2.399

Übersichtsartikel

  1. Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver Int. 2006; 26:904-911. IF: 3.84
  2. Schattenberg JM, Galle PR. Show me your signaling--and I'll tell you who you are. J.Hepatol. 2009; 51:638-639. IF: 9.,334
  3. Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis. 2009; 14:1459-71. IF: 4.397
  4. Schattenberg JM and Schuchmann M. Shortcut to death. Hepatology. 2009; 50:2040-2043. IF: 10.885
  5. Schattenberg JM. Insulin Resistance - a Link Between Inflammation and Hepatocarcinogenesis? Clinical Medicine: Endocrinology and Diabetes. 2009; 2:1-4.
  6. Schattenberg JM und Schuchmann M. Nichtalkoholische Fettlebererkrankung: Mit Entzündung und Alter steigt Risiko für fortgeschrittene Fibrose. 2009; Gastro News 1:20-21.
  7. Schattenberg JM und Schuchmann M. Nichtalkoholische Fettlebererkrankung: Wie Sie das Zirrhose- und Karzinomrisiko senken. 2009; Gastro News 3:30-34.
  8. Schattenberg JM, Galle PR. Animal models of non-alcoholic steatohepatitis: of mice and man. 2010; Dig.Dis. 28:247-254. IF: 2.06
  9. Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J.Gastroenterol.Hepatol. 2011; Suppl 1:213-219. IF: 2.41
  10. Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr.Opin.Lipidol. 2011; 22:479-488. IF: 6.636

Kasuistiken

  1. Urban PP, Hertkorn C, Schattenberg JM, Gawehn J, Hagele S, Wunsch M, Altland K (2006) Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI. J.Neurol. 253:1238-1240. IF: 1,069

Buchbeiträge

  1. Schattenberg JM and Czaja MJ. Nature and Function of Hepatic Tumor Necrosis Factor- Signaling. In: Signaling Pathways in Liver Disease (eds: Dufour JF and Clavien PA) Springer, Heidelberg, 2005:115-128.
Zurück zur vorherigen Seite